Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Toronto
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

BELLUS Health Inc

+ Add to Watchlist

BLU:CN

1.1900 CAD 0.0600 4.80%

As of 15:35:05 ET on 04/30/2015.

Snapshot for BELLUS Health Inc (BLU)

Open: 1.2100 Day's Range: 1.0700 - 1.2100 Volume: 25,432
Previous Close: 1.2500 52wk Range: 0.7200 - 1.8000 1-Yr Rtn: +40.00%

Stock Chart for BLU

No chart data available.
  • BLU:CN 1.2000
  • 1D
  • 1M
  • 1Y
1.2500
Interactive BLU Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for BLU

Current P/E Ratio (ttm) -
Estimated P/E(12/2013) -
Relative P/E vs. SPTSX -
Earnings Per Share (CAD) (ttm) -0.3000
Est. EPS (CAD) (12/2013) -
Est. PEG Ratio -
Market Cap (M CAD) 56.44
Shares Outstanding (M) 47.43
30 Day Average Volume 15,283
Price/Book (mrq) -
Price/Sale (ttm) 3.8336
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement -
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for BLU

  • Revenue
  • Net Income (M/CAD)
  • Profit Margin (%)

Company Profile & Key Executives for BLU

BELLUS Health Inc. develops drugs for rare diseases, including conditions that affect the kidneys. The Company's main operations are in a Phase III Confirmatory Study for the treatment of AA amyloidosis. BELLUS is also developing treatments for sarcoidosis and hemolytic uremic syndrome.

Roberto BelliniPresident/CEODenis GarceauSenior VP:Drug Development
Francois DesjardinsVP:FinanceTony MatzouranisVP:Business Development
More Company Profile & Key Executives for BLU

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil